[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100416347":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":40,"centralContacts":45,"locations":55,"responsibleParty":99,"collaborators":101,"id":104,"slug":105,"hasResults":106,"nctId":107,"briefTitle":108,"officialTitle":109,"acronym":50,"eligibilityCriteria":110,"healthyVolunteers":106,"sex":111,"minAge":112,"maxAge":50,"enrollmentInfo":113,"targetDuration":50,"studyType":116,"phases":117,"briefSummary":119,"conditions":120,"keywords":122,"overallStatus":58,"whyStopped":50,"lastUpdateSubmitDate":126,"lastUpdatePostDateStruct":127,"startDateStruct":130,"completionDateStruct":132,"leadSponsor":134,"locationsCount":135},{"fullName":5,"class":6},"Teclison Ltd.","INDUSTRY",[8,16],{"label":9,"type":10,"description":11,"interventionNames":12},"colorectal cancer","EXPERIMENTAL","metastatic colorectal cancer progressed on at least two lines of chemotherapy",[13,14,15],"Drug: TATE and pembrolizumab","Drug: TAS-102 pill","Drug: Regorafenib Pill",{"label":17,"type":10,"description":18,"interventionNames":19},"NSCLC","Liver metastatic NSCLC progressed on immune checkpoint inhibitors and chemotherapy",[13],[21,28,34],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","TATE and pembrolizumab","All liver metastatic lesions will be treated with TATE for maximally debulking. Pembrolizumab IV infusion per standard schedule every 3 or 6 weeks until progression or maximally 2 years.",[17,9],[27],"TATE: Trans-arterial Tirapazamine Embolization;",{"type":22,"name":29,"description":30,"armGroupLabels":31,"otherNames":32},"TAS-102 pill","The comparator of the mCRC arm is TAS-102 at 60 mg BID 5 days per week for 2 weeks then 2 weeks off.",[9],[33],"LONSURF",{"type":22,"name":35,"description":36,"armGroupLabels":37,"otherNames":38},"Regorafenib Pill","As an alternative to TAS-102 per treating physician's discretion. If selected, Regorafenib 160 mg oral daily for 3 weeks on and one week off, every 4 weeks per cycle. Do not take Regoarefnib if taking TAS-102.",[9],[39],"STIVARGA",[41],{"name":42,"affiliation":43,"role":44},"Ray Lee","Teclison Limited","STUDY_DIRECTOR",[46,52],{"name":47,"role":48,"phone":49,"phoneExt":50,"email":51},"Ray Lee, MD. PhD.","CONTACT","8043341076",null,"ray.lee01@teclison.com",{"name":53,"role":48,"phone":50,"phoneExt":50,"email":54},"Chiwei Lu","chiwei.lu4@teclison.com",[56,74,88],{"facility":57,"status":58,"city":59,"state":60,"zip":61,"country":62,"countryCode":63,"cosmosGeoPoint":64,"geoPoint":69,"contacts":70},"University of California, Irvine Medical Center","RECRUITING","Orange","California","92868","United States","US",{"type":65,"coordinates":66},"Point",[67,68],-117.85311,33.78779,{"lat":68,"lon":67},[71],{"name":72,"role":48,"phone":50,"phoneExt":50,"email":73},"Miranda Duron","mnduron@hs.uci.edu",{"facility":75,"status":58,"city":76,"state":50,"zip":50,"country":77,"countryCode":78,"cosmosGeoPoint":79,"geoPoint":83,"contacts":84},"China Medical University Hsinchu Hospital","Hsinchu","Taiwan","TW",{"type":65,"coordinates":80},[81,82],120.96861,24.80361,{"lat":82,"lon":81},[85],{"name":86,"role":48,"phone":50,"phoneExt":50,"email":87},"sandy Lai","sandy6618@teclison.com",{"facility":89,"status":58,"city":90,"state":50,"zip":50,"country":77,"countryCode":78,"cosmosGeoPoint":91,"geoPoint":95,"contacts":96},"Chung Shan Medical University Hospital","Taichung",{"type":65,"coordinates":92},[93,94],120.6839,24.1469,{"lat":94,"lon":93},[97],{"name":98,"role":48,"phone":50,"phoneExt":50,"email":87},"Sandy Lai",{"type":100,"investigatorFullName":50,"investigatorTitle":50,"investigatorAffiliation":50,"oldNameTitle":50,"oldOrganization":50},"SPONSOR",[102],{"name":103,"class":6},"Merck Sharp & Dohme LLC","100416347","phase-2-tate-and-pembrolizumab-mk3475-in-mcrc-and-nsclc-100416347",false,"NCT04701476","TATE and Pembrolizumab (MK3475) in mCRC and NSCLC","An Open Label Phase II Study for the Treatment of Liver Metastatic Colorectal Cancer and Non-Small Cell Lung Cancer With a Combination of TATE (Trans-Arterial Tirapazamine Embolization) and Pembrolizumab","Inclusion Criteria:\n\n* Liver metastatic MSS-mCRC or NSCLC without EGFR or AKT mutations\n* mCRC progressed on at least two lines of standard chemotherapy; or\n* NSCLC progressed on chemotherapy and an immune checkpoint inhibitor\n* Measurable disease\n* ECOG 0-1\n* At least 4 weeks from prior chemotherapy and free from chemo-related toxicity\n* Adequate organ function\n\nExclusion Criteria:\n\n* Prior organ transplantation\n* Liver metastasis more than 50%\n* Oxygen saturation less than 92% in room air\n* Prior autoimmune disorder\n* CNS metastasis\n* Major GI bleeding in the last 2 months","ALL","18 Years",{"count":114,"type":115},110,"ESTIMATED","INTERVENTIONAL",[118],"PHASE2","Patients with refractory metastatic colorectal cancer or non-small cell lung cancer with liver metastasis treated with Trans-arterial Tirapazamine Embolization along with Pembrolizumab.",[121],"Colorectal Cancer; Lung Cancer",[9,17,123,124,125],"pembrolizumab","tirapazamine","Liver metastasis","2026-04-15",{"date":128,"type":129},"2026-04-16","ACTUAL",{"date":131,"type":129},"2021-05-20",{"date":133,"type":115},"2027-09-30",{"name":5,"class":6},3]